Telbivudine in the treatment of chronic hepatitis B

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 13-22

  Hadziyannis, Stephanos J ^a   Vassilopoulos, Dimitrios ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chronic hepatitis B; HBV DNA; HBV resistance; Lamivudine; LdT; Predictors of response; Telbivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EUROPE; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LONG TERM CARE; MONOTHERAPY; MUSCLE WEAKNESS; MYOPATHY; NONHUMAN; PATIENT MONITORING; PREDICTION; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; SIDE EFFECT; STEADY STATE; STRUCTURE ACTIVITY RELATION; UNITED STATES; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES;

EID: 49149120289     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.13     Document Type: Review

References (50)

1. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 4(8), 936-962 (2006).
2. Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Expert Opin. Biol. Ther. 6(9), 913-921 (2006).
3. Chang TT, Jia JD, Omata M, Yoon SK. New therapies for chronic hepatitis B infection. Liver Int. 26 (Suppl. 1) 230-237 (2006).
4. Jones R, Nelson M. Novel anti-hepatitis B agents: a focus on telbivudine. Int. J. Clin. Pract. 60(10), 1295-1299 (2006).
5. Hu P, Jiang J, Wang H et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J. Clin. Pharmacol. 46(9), 999-1007 (2006).
6. Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob. Agents Chemother. 50(7), 2309-2315 (2006).
7. Kim JW, Park SH, Louie SG. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann. Pharmacother. 40(3), 472-478 (2006).
8. Zhou XJ, Lim SG, Lloyd DM et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob. Agents Chemother. 50(3), 874-879 (2006).
9. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2), 528-536 (2005).
10. Han SH. Telbivudine: a new nucleoside analog for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs 14(4), 511-519 (2005).
11. Hadziyannis SJ, Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert Opin. Emerg. Drugs 9(2), 207-221 (2004).
12. Lai CL, Lim SG, Brown NA et aql. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40(3), 719-726 (2004).
13. Yuen MF, Lai CL. Telbivudine: an upcoming agent for chronic hepatitis B. Expert Rev. Anti Infect. Ther. 3(4), 489-494 (2005).
14. Di Bisceglie AM, Lai CL, Gane E et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal 2-year efficacy. Hepatology 44(4 Suppl. 1), 230A (2006).
15. Poynard T, Chutaputti A, Hwang SG et al. Sustained off-treatment HBeAg responses in telbivudine treated HBeAg-positive patients fiom the GLOBE study. J. Hepatol. 46(Suppl. 1), S27 (2007).
16. Standring DN, Seifer M, Patty A, Chapron C. HBV resistance determination from the telbivudine GLOBE registration trial. J. Hipatol. 44(Suppl. 1), 191 (2006).
17. Lai CL, Gane E, Liaw YF et al. Telbivudine (LdT) vs lamivudine for chronic hepatitis B: first-year results from the international Phase III GLOBE trial. Hepatology 42(4 Suppl. 1), 748A (2005).
18. Lai CL, Gane E, Chao-Wei H et al. Two-year results from the GLOBE trial in patients with chronic hepatitis B: greater clinical and antiviral efficacy for telbivudine (LtD) vs lamivudine. Hepatolgy 44(4 Suppl. 1), 222A (2006).
19. Marcellin P, Chan HLY, Lai CL et al. In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy. J. Hepatol. 46(Suppl. 1), S193 (2007).
20. Safadi R. Xie Q, Chen Y et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J. Hepatol. 46(Suppl. 1), S196 (2007).
21. Thongsawat S, Lai Cl, Gane G. Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: results from the GLOBE study. J. Hepatol. 44(Suppl. 1), 49 (2007).
22. Yuen MF. Sablon E, Hui CK et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34(4 Pt 1), 785-791 (2001).
23. Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin. Investig. Drugs 16(6), 777-786 (2007).
24. Van Bommel F, Brodzinski A, Mihm U et al. Multifactorial analysis of host and virus related risk factors for the development of viral resistance during long-term lamivudine treatment of HBV infection over up to nine years. J. Hepatol. 46(Suppl. 1), S198 (2007).
25. Marcellin P, Chan HLY, Lai CL et al. 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine. J. Hepatol. 46(Suppl. 1), S55 (2007).
26. Lai CL, Leung N, Teo EK et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs. lamivudine vs combination treatment in hepatitis B patients: two-year results. Gastroenterology 128 (Suppl. 1), A692 (2005).
27. Golitsina N, Danehy F, Fellows R et al. Phosphorylation of telbivudine by three enzymes: implications for anti-hepatitis B virus activity in vitro and in the clinic. Hepatology 44(4 Suppl. 1) 561A (2006).
28. Cooksley H, Hou J-L, Vitek L et al. Impact of nucleosite treatment on antiviral T-cell reactivity in chronic hepatitis B: major differences depending on early viral suppression, HBeAg status and HBV genotype. Hepatology 44(4 Suppl. 1) 547A-548A (2006).
29. Bartholomeusz AL, Yuen L, Locarnini S, Kuiper M. Understanding HBV rsistance to telbivudine: molecular modelling and data basis mining. J. Hepatol. 46(Suppl. 1), S185 (2007).
30. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 51(4), 761-785 (2003).
31. Wang P, Hong JH, Cooperwood JS, Chu CK. Recent advances in L-nucleosides: chemistry and biology. Antiviral Res. 40(1-2), 19-44 (1998).
32. Bryant ML, Bridges EG, Placidi L et al. Antiviral L-nudeosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45(1), 229-235 (2001).
33. Standring DN, Bridges EG, Placidi L et al. Antiviral β-L-nucleosidcs specific for hepatitis B virus infection. Antivir. Chem. Chemother. 12(Suppl. 1) 119-129 (2001).
34. Hernandez-Santiago B, Placidi L, Cretton-Scott E et al. Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46(6), 1728-1733 (2002).
35. Zhou XJ, Marbury TC, Alcorn HW et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob. Agents Chemother. 50(5), 1721-1726 (2006).
36. Zhou XJ, Myers M, Chao G, Dubuc G, Brown N. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function. J. Hepatol. 40 (Suppl. 1), 134 (2004).
37. Brown CA; Smith F; Laessig KA. Creatine kinase (CK) elevations and muscle toxicities associated with chronic telbivudine (LdT) use in prospective clinical trials. Hepatology 46(4 Suppl. 1) 655A (2007).
38. Han SH, Lai CL, Gane E et al. Telbivudine GLOBE trial year two: efficacy, safety and predictors of outcome in patients with chronic hepatitis B. Presented at: Digestive Disease Week. Washington, DC, USA, 19-24 May, 2007.
39. Ruiz-Sancho A, Sheldon J, Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin. Biol. Ther. 7(5), 751-761 (2007).
40. Rivldn A. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B. Drugs Today (Barc.) 43(4), 201-220 (2007).
41. Dienstag J, Easley C, Kirkpatrick P. Telbivudine. Nat. Rev. Drug Discov. 6(4), 267-268 (2007).
42. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. i Antivir. Ther. 9(5), 679-693 (2004).
43. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil far HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352(26), 2673-2681 (2005).
44. Gane E, Lai Cl, Min A, Heathcote J. Adefovir salvage therapy for virologic breakthrough in telbivudine-tireated patients from the GLOBE study. J. Hepatol. 46(Suppl. 1), S187 (2007).
45. Standring DN, Patty A, Chapron C et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the International GLOBE Trial. Presented at: Digestive Disease Week. Washington DC, USA, 19-24 May, 2007.
46. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gutroenterology 131(6), 1743-1751 (2006).
47. Hadziyannis AS, Mitsoula P, Hadziyannis E. Monitoring serum HBV DNA levels with the TaqMan technique during treatment of HBeAg(-) chronic hepatitis B with lamivudine. Hepatology 42(4 Suppl. 1), 726A (2005).
48. Locarnini S, Qi X, Arterbrun S. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB. J. Hepatol. 42(Suppl. 1), S17 (2005).
49. Bzowej H, Chan H, Lai CL et al. A randomized trial of telbivudine (LdT) vs adefovir for HBeAg-positive chronic hepatitis B: final week 52 results. Hepatology 44(4 Suppl. 1) (2006).
50. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45(2), 507-539 (2007).